Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-64005 in Major Depressive Disorder
NCT04244253Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OPC-64005 in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Mar 2020; status: completed.
02
Drugs
OPC-64005
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04244253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244253.